Hepaglide 2.4mg Injection

Q1: What is Hepaglide 2.4mg used for?

Hepaglide 2.4mg is the maximum maintenance dose of injectable semaglutide from Zydus Healthcare, used for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities, alongside a reduced-calorie diet and increased physical activity.

Q2: How does Hepaglide 2.4mg compare to Wegovy 2.4mg in efficacy?

Both deliver semaglutide 2.4mg weekly. As a bioequivalent product, Hepaglide 2.4mg achieves the same ~15% average body weight reduction over 68 weeks with lifestyle changes. Zydus Healthcare's manufacturing standards ensure consistent product quality.

Q3: What makes Hepaglide 2.4mg the most affordable Wegovy equivalent?

Hepaglide is produced by Zydus Healthcare's Indian manufacturing operations under generic pharmaceutical economics — no innovation R&D costs, lower labour costs, and India's drug pricing structure. This results in pricing that is typically 70–80% below the global Wegovy price.

Q4: How long should I remain on Hepaglide 2.4mg?

Indefinitely, in most cases. Semaglutide is a long-term treatment analogous to antihypertensive or cholesterol-lowering therapy. Stopping leads to weight regain in the majority of patients. Annual review with your prescriber should assess ongoing benefit and any need to adjust treatment.

Q5: What monitoring is required on Hepaglide 2.4mg?

Regular body weight tracking, HbA1c (in diabetic patients), renal function, and liver enzymes annually. Gallbladder ultrasound if abdominal symptoms develop. Ophthalmological review for patients with diabetic retinopathy. Nutritional assessment for patients with very low food intake.

Q6: Does Hepaglide 2.4mg affect bone density?

Rapid weight loss can modestly reduce bone mineral density. Weight-bearing exercise, adequate calcium (1000–1200 mg/day), and vitamin D supplementation are recommended to protect bone health during significant weight loss on Hepaglide 2.4mg.

Q7: Can patients with type 2 diabetes use Hepaglide 2.4mg?

Yes. Hepaglide 2.4mg provides excellent glycaemic benefit alongside weight loss in type 2 diabetes. As HbA1c normalises, concurrent diabetes medications may need dose reduction or discontinuation under prescriber supervision.

Q8: Is there a specific diet I must follow on Hepaglide 2.4mg?

No specific diet is mandated, but a reduced-calorie diet (500–750 kcal below maintenance) rich in lean protein and vegetables amplifies the medication's weight-loss effect. Your prescriber may refer you to a dietitian for personalised nutritional support.

Q9: Can I switch from Wegovy 2.4mg to Hepaglide 2.4mg without any interruption?

Yes. Switching between bioequivalent products at the same dose can be done seamlessly. Administer Hepaglide on the same weekly schedule as your previous Wegovy injection without any dose adjustment or re-titration.

Q10: What is the cardiovascular benefit data for Hepaglide 2.4mg?

The SELECT trial demonstrated that semaglutide 2.4mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in overweight/obese adults with established cardiovascular disease and without diabetes. Hepaglide 2.4mg, as the equivalent dose, is expected to confer the same benefit.